Targeting HPV Consequences in a Cervical Cancer Clinical Trial

在宫颈癌临床试验中针对 HPV 后果

基本信息

批准号：
9052455
负责人：
DORIS Mangiaracina BENBROOK
金额：
$ 59.51万
依托单位：
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2021-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9052455
关键词：
Adjuvant Adverse effects Aftercare Antineoplastic Agents Apoptosis Binding Bioavailable Biological Markers Biopsy Cancer Etiology Cancer Patient Cancer cell line Cell Cycle Cell Cycle Arrest Cell Cycle Checkpoint Cell Cycle Progression Cell Cycle Proteins Cervical Cervical dysplasia Cervix Neoplasms Cessation of life Chemoprevention Clinical Trials Cold Therapy Congresses Cyclin A Cyclin D1 Cyclins Defect Detection Developing Countries Development Drug Kinetics E2F transcription factors EGF gene Epidermal Growth Factor Receptor Event Formulation Future G1 Arrest Genes Genome Genomic DNA Growth Histology Human Human Papillomavirus Human papillomavirus 16 Infection Infertility Investigational Drugs Knock-out Knowledge Lesion Malignant Neoplasms Malignant neoplasm of cervix uteri Mediating Mus Mutation Oral Oral Administration Pathway interactions Patients Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Pharmacodynamics Phase Phosphorylation Proteins Quality of life Regulation Resistance Retinoblastoma Risk S Phase SHetA2 Staging Suppositories TP53 gene Testing Therapeutic Therapeutic Agents Time Tissues Toxic effect Transfection Transgenic Mice Treatment-related toxicity Tumor Suppressor Proteins Ubiquitination United States Food and Drug Administration Vaccination Vagina Vaginal Suppository Vaginal delivery procedure Woman cancer cell cancer clinical trial cancer therapy capsule carcinogenesis cell transformation cervical cancer prevention chemotherapy cost high risk improved in vitro activity in vivo mutant pharmacodynamic biomarker preclinical study prevent public health relevance retinoblastoma tumor suppressor small molecule tumor tumor progression vaccine evaluation

项目摘要

DESCRIPTION (provided by applicant): High risk human papillomavirus (HPV) causes cervical dysplasia which can progress to cervical cancer, the second leading cause of cancer-related deaths among women. Therapeutic treatments for cervical cancer are highly toxic and often negatively impact quality of life. Cervical cancer is prevented by detection and destruction of cervical dysplasia involving significant cost, discomfort and potential loss of fertility, althogh the majority of these lesions will not progress to cancer. We developed a non-toxic cancer drug that has a mechanistic profile suitable for application in cervical dysplasia and cancer. Our drug, called SHetA2 (NSC 721689) counteracts the cell cycle regulatory consequences of high risk HPV. Extensive preclinical studies of SHetA2 demonstrated cancer therapeutic and chemoprevention activity in vitro and in vivo, lack of mutagenicity or teratogenicity, no toxicity and a pharmacologic profile suitable for an oral therapeutic agent. A pre-Investigational New Drug (IND) meeting report from the US Food and Drug Administration (FDA) listed no obstacles for our moving forward to a Phase 0 Clinical trial of SHetA2 in cervical cancer. In this project, w hypothesize that SHetA2 causes G1 arrest and apoptosis in human and murine cervical tumors by counteracting the alterations in cyclin D1 and other cell cycle regulatory proteins caused by HPV. We will test this hypothesis by conducting a Phase 0 clinical trial in Stage IB2-IVB cervical cancer patients to determine if oral administration of SHetA2 capsules can achieve systemic and cervical tissue concentrations of SHetA2 known to regulate cyclins A, D1 and E, and RB phosphorylation events. Pre- and post-treatment cervical tumor biopsies and a time course of collected peripheral blood mononuclear cells (PBMCs) collected in this trial will be used to determine which Rb pathway defects found in cervical cancer are altered by SHetA2 treatment. In addition, we will compare oral capsule and vaginal suppository SHetA2 formulations for alterations of cell cycle regulatory proteins in association with reduction of cervical tumor formation in K14-HPV16 transgenic mice. Cell cycle proteins, such as cyclins A, D and E, that are counter- regulated by HPV and SHetA2 will be tested for their direct involvement in SHetA2 regulation of G1 cell cycle arrest and apoptosis. These studies will lay the groundwork for future clinical trials in cervical dysplasia and cancer by determining the pharmacokinetics (PK) and pharmacodynamics (PD) of SHetA2, and by determining whether oral or vaginal delivery will achieve higher tissue concentrations of SHetA2, greater alterations in cell cycle proteins and greater prevention of cervical cancer in HPV transgenic mice. Our mechanistic studies will develop candidate PD biomarkers for use in future clinical trials planned for cervical dysplasia and will provide increased knowledge of HPV associated cell cycle defects in cervical dysplasia and cancer.

描述（由申请人提供）：高危人乳头瘤病毒 (HPV) 会导致宫颈发育不良，进而发展为宫颈癌，宫颈癌是导致女性癌症相关死亡的第二大原因。宫颈癌的治疗方法具有剧毒，并且通常会对治疗质量产生负面影响。通过检测和破坏宫颈发育不良来预防宫颈癌会带来巨大的成本、不适和可能导致生育能力的丧失，尽管大多数这些病变不会发展为癌症，但我们开发了一种无毒的抗癌药物。我们的药物适用于宫颈发育不良和癌症的机制特征。 SHetA2 (NSC 721689) 可以抵消高危 HPV 的细胞周期调节后果。广泛的临床前研究表明，SHetA2 具有体外和体内癌症治疗和化学预防活性，无致突变性或致畸性，无毒性，并且具有适合口服的药理学特征。美国食品和药物管理局 (FDA) 的预研究新药 (IND) 会议报告列出了我们进入一期试验的任何障碍。 0 SHetA2 在宫颈癌中的临床试验，我们发现 SHetA2 通过抵消 HPV 引起的细胞周期蛋白 D1 和其他细胞周期调节蛋白的变化，导致人类和小鼠宫颈肿瘤 G1 期停滞和细胞凋亡。通过在 IB2-IVB 期宫颈癌患者中进行 0 期临床试验，以确定口服 SHetA2 胶囊是否可以达到已知调节细胞周期蛋白的 SHetA2 的全身和宫颈组织浓度本试验中收集的 A、D1 和 E 以及 RB 磷酸化事件和治疗后宫颈肿瘤活检以及收集的外周血单核细胞 (PBMC) 的时间过程将用于确定宫颈癌中发现的 Rb 通路缺陷。此外，我们将比较口服胶囊和阴道栓剂 SHetA2 制剂中细胞周期调节蛋白的改变与 K14-HPV16 转基因中宫颈肿瘤形成的减少相关。将测试受 HPV 和 SHetA2 反向调节的细胞周期蛋白，例如细胞周期蛋白 A、D 和 E，以确定它们是否直接参与 SHetA2 对 G1 细胞周期停滞和细胞凋亡的调节。这些研究将为未来奠定基础。通过确定 SHetA2 的药代动力学 (PK) 和药效学 (PD)，以及确定口服或阴道给药是否会实现更高的 SHetA2 组织浓度、更大的细胞改变，进行宫颈发育不良和癌症的临床试验我们的机制研究将开发候选 PD 生物标志物，用于计划用于宫颈发育不良的未来临床试验，并将提供更多关于宫颈发育不良和癌症中 HPV 相关细胞周期缺陷的知识。